Literature DB >> 17330788

Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.

Philip M McKenna1, Martin L Koser, Kevin R Carlson, David C Montefiori, Norman L Letvin, Amy B Papaneri, Roger J Pomerantz, Bernhard Dietzschold, Peter Silvera, James P McGettigan, Matthias J Schnell.   

Abstract

We analyzed the safety and immunogenicity of attenuated rabies virus vectors expressing simian-human immunodeficiency virus (SHIV)-1(89.6P) Env or simian immunodeficiency virus (SIV)(mac239) Gag in rhesus macaques. Four test macaques were immunized with both vaccine constructs, and 2 control macaques received an empty rabies vector. Seroconversion against rabies virus glycoprotein (G) and SHIV(89.6P) Env was detected after the initial immunization, but no cellular responses against SHIV antigens were observed. HIV/SIV-specific immune responses were not enhanced by boosts with the same vectors. Therefore, we constructed vectors expressing SHIV(89.6P) Env and SIV(mac239) Gag in which the rabies G was replaced with the G protein of vesicular stomatitis virus (VSV). Two years after initial immunization, a boost with the rabies-VSV G vectors resulted in SIV/HIV-specific immune responses. Upon challenge with SHIV(89.6P) test macaques controlled the infection, whereas control macaques had high levels of viremia and a profound loss of CD4(+) T cells, with 1 control macaque dying of an AIDS-like disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17330788     DOI: 10.1086/512243

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  21 in total

Review 1.  Experimental rabies vaccines for humans.

Authors:  James P McGettigan
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

2.  Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.

Authors:  Celestine N Wanjalla; Elizabeth J Faul; Emily A Gomme; Matthias J Schnell
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

3.  Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene.

Authors:  Jonathan Cenna; Gene S Tan; Amy B Papaneri; Bernhard Dietzschold; Matthias J Schnell; James P McGettigan
Journal:  Vaccine       Date:  2008-09-18       Impact factor: 3.641

Review 4.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

5.  PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity.

Authors:  Christoph Wirblich; Gene S Tan; Amy Papaneri; Peter J Godlewski; Jan Marc Orenstein; Ronald N Harty; Matthias J Schnell
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

6.  Characterization of a single-cycle rabies virus-based vaccine vector.

Authors:  Emily A Gomme; Elizabeth J Faul; Phyllis Flomenberg; James P McGettigan; Matthias J Schnell
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

7.  Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.

Authors:  Jean D Boyer; Tara M Robinson; Michele A Kutzler; Gordon Vansant; David A Hokey; Sanjeev Kumar; Rose Parkinson; Ling Wu; Maninder K Sidhu; George N Pavlakis; Barbara K Felber; Charles Brown; Peter Silvera; Mark G Lewis; Joseph Monforte; Thomas A Waldmann; John Eldridge; David B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

8.  Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge.

Authors:  Elizabeth J Faul; Pyone P Aye; Amy B Papaneri; Bapi Pahar; James P McGettigan; Faith Schiro; Inna Chervoneva; David C Montefiori; Andrew A Lackner; Matthias J Schnell
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

9.  Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity.

Authors:  Elizabeth J Faul; Celestine N Wanjalla; James P McGettigan; Matthias J Schnell
Journal:  Virology       Date:  2008-10-21       Impact factor: 3.616

Review 10.  Development of replication-competent viral vectors for HIV vaccine delivery.

Authors:  Christopher L Parks; Louis J Picker; C Richter King
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.